Ticilimumab. Anti-CTLA4-antibody, oncolytic

被引：2

作者：

Wang, Y.

机构：

[1] Frederick, MD 21702

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 04期

关键词：

D O I：

10.1358/dof.2007.032.04.1089088

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ticilimumab (tremelimumab, CP-675206), a fully human IgG 2 monoclonal antibody targeting CTLA-4, has been developed to boost the body's immune system to target tumor cells. Ticilimumab showed antitumor activity and an acceptable safety profile in preclinical studies. Phase I clinical trials demonstrated that it can be safely administered to patients with advanced melanoma at up to 15 mg/kg im. Dose-limiting toxicities and autoimmune phenomena included diarrhea, dermatitis and hypothyroidism. Antitumor responses in patients with melanoma who received ticilimumab were attributed to improved T-cell immunity. Clinical trials are ongoing in melanoma, renal cell carcinoma, colorectal adenocarcinoma and non-small cell lung cancer (NSCLC).

引用

页码：337 / 340

页数：4

共 31 条

[1] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].

BRUNET, JF ;

DENIZOT, F ;

LUCIANI, MF ;

ROUXDOSSETO, M ;

SUZAN, M ;

MATTEI, MG ;

GOLSTEIN, P .

NATURE, 1987, 328 (6127) :267-270

[2]

BULANHAGUI CA, 2006, 42 ANN M AM SOC CLIN

[3]

CANNIFF PC, 2004, P AM ASS CANC RES AA, V45

[4] CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].

Chambers, CA ;

Kuhns, MS ;

Egen, JG ;

Allison, JP .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594

[5]

GOMEZNAVARRO J, 2006, J CLIN ONCOL S, V24

[6]

HANSON DC, 2004, P AM ASS CANC RES AA, V45

[7] CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES [J].

HARDING, FA ;

MCARTHUR, JG ;

GROSS, JA ;

RAULET, DH ;

ALLISON, JP .

NATURE, 1992, 356 (6370) :607-609

[8] IDENTIFICATION OF AN ALTERNATIVE CTLA-4 LIGAND COSTIMULATORY FOR T-CELL ACTIVATION [J].

HATHCOCK, KS ;

LASZLO, G ;

DICKLER, HB ;

BRADSHAW, J ;

LINSLEY, P ;

HODES, RJ .

SCIENCE, 1993, 262 (5135) :905-907

[9] Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients [J].

Hodi, FS ;

Mihm, MC ;

Soiffer, RJ ;

Haluska, FG ;

Butler, M ;

Seiden, MV ;

Davis, T ;

Henry-Spires, R ;

MacRae, S ;

Willman, A ;

Padera, R ;

Jaklitsch, MT ;

Shankar, S ;

Chen, TC ;

Korman, A ;

Allison, JP ;

Dranoff, G .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4712-4717

[10]

JENKINS MK, 1991, J IMMUNOL, V147, P2461

← 1 2 3 4 →